… of a personalized TCV may be an effective strategy. The choice of target antigen is a
major determinant of immunogenicity … , or by personalized approaches targeting cancer-associated …

… In conclusion, a potent personalized cancer vaccine with strong immunogenicity, can
diversify the tumor-specific T cell repertoire, activate immune systems, activate robust effective T …

… had stable disease (SD), suggesting that Nous-209 is safe and immunogenic and may …
Another phase I study, ADXS-NEO-2, targeted personalized neoantigens for each cancer patient. …

… Safety and immunogenicity of a personalized neoantigen-Listeria vaccine in cancer patients
[… In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; …

… testing Lm cancer vaccines across a wide variety of cancers, … Here, we assessed the
immunogenicity of an Lm vaccine … trials testing personalized cancer vaccines between 2017 …

… responses triggered by tumor vaccines or checkpoint inhibitors. Here we explored the
therapeutic potential of combining radiation therapy (RT) and a prostate cancer vaccine (ADXS-…

… immunogenic context (a “vaccine”), would, due to the preferential targeting of cancer cells,
enable relatively safe and … in patients with solid tumors showed that personalized neoantigen …

… patients demonstrated the safety and immunogenicity of a personal neoantigen long-peptide
vaccine … A study evaluating the feasibility of a similar personal neoantigen vaccine in …

… Considerable research is being done on using recombinant bacteria as cancer vaccines
to immunize cancer patients against their tumors or to kill the tumor cells directly as oncolytic …